Empagliflozin/linagliptin

Empagliflozin/linagliptin
Combination of
Empagliflozin	SGLT2 inhibitor
Linagliptin	DPP-4 inhibitor
Clinical data
Trade names	Glyxambi
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Glyxambi;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	A10BD19 (WHO) ;
Legal status
Legal status	AU: ; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	864070-44-0 ; 668270-12-0 ;
PubChem CID	85364159;
UNII	HDC1R2M35U; 3X29ZEJ4R2 ;
KEGG	D10588 ;
Chemical and physical data
Formula	C48H55ClN8O9
Molar mass	923.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C.COC1C(C(C(C(O1)C2=CC(=C(C=C2)Cl)CC3=CC=C(C=C3)OC4CCOC4)O)O)O;
	InChI InChI=1S/C25H28N8O2.C23H27ClO7/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20;1-28-23-21(27)19(25)20(26)22(31-23)14-4-7-18(24)15(11-14)10-13-2-5-16(6-3-13)30-17-8-9-29-12-17/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3;2-7,11,17,19-23,25-27H,8-10,12H2,1H3/t17-;17-,19+,20+,21-,22-,23-/m10/s1; Key:POMOOZUJAXCEKG-QPVQWCQSSA-N;
	(verify)

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth.

The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .

It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016.